Triapine(Triapine) - 药物靶点：RNR_在研适应症：腺鳞癌，宫颈鳞状细胞癌，鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Triapine、3-AP、NSC#663249

+ [5]

靶点

RNR

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病其他疾病+ [2]

在研适应症

腺鳞癌宫颈鳞状细胞癌鳞状细胞癌+ [8]

非在研适应症

腺泡细胞癌急性白血病急性早幼粒细胞白血病+ [63]

原研机构

Nanotherapeutics, Inc.

在研机构

National Cancer Institute

Nanopharmaceutics, Inc.初创企业

Nanotherapeutics, Inc.

非在研机构

Vion Pharmaceuticals, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS号143621-35-6

关联

33

项与 Triapine 相关的临床试验

NCT06410248 / Recruiting临床1期IIT

A Phase 1 Adaptive Dose Escalation with Dose Expansion Study of Triapine in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

开始日期2024-07-23

申办/合作机构

Northwestern University

[+2]

NCT05724108 / Recruiting临床2期IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

开始日期2023-08-30

申办/合作机构

National Cancer Institute

NCT04494113 / Suspended早期临床1期IIT

A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma

This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and bilateral salpingo-oophorectomy). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding triapine to the usual approach of surgery followed by chemotherapy alone or in combination with radiation therapy may help to slow the growth of uterine cancer.

开始日期2022-02-08

申办/合作机构

National Cancer Institute

100 项与 Triapine 相关的临床结果

登录后查看更多信息

100 项与 Triapine 相关的转化医学

登录后查看更多信息

100 项与 Triapine 相关的专利（医药）

登录后查看更多信息

312

项与 Triapine 相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

Article

作者: Randall, Leslie M ; Vargo, John ; Kohn, Elise C ; Orr, Brian ; Ivy, S Percy ; Courtney-Brooks, Madeleine ; Mahdi, Haider ; Behr, Sarah ; Lin, Yan ; Fabian, Denise ; Beriwal, Sushil ; Gallion, Holly ; Richardson, Debra L ; Chu, Edward ; Beumer, Jan H ; Kunos, Charles ; Huang, Marilyn ; Taylor, Sarah E ; Ueland, Frederick ; Girda, Eugenia ; Olawaiye, Alexander B ; Chauhan, Aman ; Sullivan, Stephanie A ; Cooper, Kristine L ; Christner, Susan M

BACKGROUND:

The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation.

METHODS:

We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed.

RESULTS:

19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance.

CONCLUSIONS:

Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure.

CLINICAL TRIAL REGISTRATION:

NCT02595879.

2024-12-01·BIOORGANIC CHEMISTRY

Synthesis of 5-hydroxyisatin thiosemicarbazones, spectroscopic investigation, protein-ligand docking, and in vitro anticancer activity

Article

作者: Nath Yadav, Paras ; Sharma, Pratibha ; Chikara, Anshul ; Kumar, Piyush ; Barua, Ayanti ; Adhikari Subin, Jhashanath ; Raj Pokharel, Yuba ; Chaudhary, Upendra ; Mahiya, Kuldeep

A series of novel modifications were performed at the N(4) position of 5-hydroxyisatin thiosemicarbazone (TSC). The structure-activity approach is applied to design and synthesize derivatives by condensing thiosemicarbazides with 5-hydroxy isatin. The TSCs were characterized by various spectroscopic techniques viz. FTIR, ¹H NMR, ¹³C NMR, UV-Vis, HRMS data, CHN elemental analysis, and single crystal X-ray diffraction. Biological evaluation of the synthesized compounds revealed the anticancer potency of the TSC analogues against breast cancer (MD-AMD-231, MCF-7), lung cancer (A549, NCI-H460), prostate cancer (PC3), and skin cancer (A431). The molecules, L2, L3, and L6 showed activity in the micromolar range (IC₅₀; 0.19-2.19 μM). L6 exhibited the highest potency against skin cancer A431 cell line, with an IC₅₀ of 0.19 μM compared to 1.8 μM with triapine and showed low toxicity against PNT-2 cells with an SI index of >100 μM. The mechanistic study revealed that L6 inhibited cancer cell proliferation, colony formation, and 3-dimensional spheroid formation by targeting the Ras/MAPK axis. It induced DNA damage and impaired DNA damage repair machinery, which led to the accumulation of DSB. Also, it lowered the ERK1/2 expression, which affected the caspase 3 activity and showed higher binding affinity compared to the FDA-approved drug Lenalidomide in molecular docking studies. Our findings demonstrated the possible future anticancer drug potency of L6 in the skin cancer A431 cells.

2024-12-01·GLIA

Identification of astrocyte‐like cells in an adult ascidian during regeneration of the central nervous system

Article

作者: Monteiro‐de‐Barros, Cintia ; de Andrade Gomes, Carlos Augusto Borges ; Portal, Taynan Motta ; Nunes‐da‐Fonseca, Rodrigo ; Allodi, Silvana ; Medina, Bianca Nicole Santos Paes

Abstract:

The mechanisms underlying regeneration of the central nervous system (CNS) following lesions have been studied extensively in both vertebrate and invertebrate models. To shed light on regeneration, ascidians, a sister group of vertebrates and with remarkable ability to regenerate their brains, constitute an appropriate model system. Glial cells have been implicated in regeneration in vertebrates; however, their role in the adult ascidian CNS regeneration is unknown. A model of degeneration and regeneration using the neurotoxin 3‐acetylpyridine (3AP) in the brain of the ascidian Styela plicata was used to identify astrocyte‐like cells and investigate their role. We studied the CNS of control ascidians (injected with artificial sea water) and of ascidians whose CNS was regenerating (1 and 10 days after the injection with 3AP). Our results show that the mRNA of the ortholog of glutamine synthetase (GS), a glial‐cell marker in vertebrates, is increased during the early stages of regeneration. Confirming the identity of GS, the protein was identified via immunostaining in a cell population during the same regeneration stage. Last, a single ortholog of GS (GSII) is present in ascidian and amphioxus genomes, while two types exist in fungi, some invertebrates, and vertebrates, suggesting that ascidians have lost the GSI type. Taken together, our findings revealed that a cell population expressing glial‐cell markers may play a role in regeneration in adult ascidians. This is the first report of astrocyte‐like cells in the adult ascidian CNS, and contributes to understanding of the evolution of glial cells among metazoans.

4

项与 Triapine 相关的新闻（医药）

2024-05-14

·PRNewswire

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

临床1期寡核苷酸

2022-11-02

·PRNewswire

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 [email protected] SOURCE Nanopharmaceutics, Inc.

放射疗法

2022-11-02

·BioSpace

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the NCI Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 jtalton@nanopharmaceutics.com View original content: SOURCE Nanopharmaceutics, Inc.

放射疗法

100 项与 Triapine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺鳞癌	临床3期	美国	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	美国	National Cancer Institute	2016-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02595879 (CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 ... 更多	21	triapine (All Participants)	淵願糧衊壓願窪襯範構(獵積顧壓襯製鑰構繭襯) = 鹽網構襯鏇襯鑰醖衊顧鑰構獵壓齋齋願繭顧齋 (艱選鑰顧膚鬱廠鹽積醖, 遞齋鬱壓鑰壓繭窪鬱鬱 ~ 遞製襯網願鹹餘鑰齋醖)	-	2024-10-16
				Triapine (Triapine (100mg) + Chemoradiation))	鬱遞壓衊構簾範夢構築(網淵鑰範範糧鏇淵鏇鏇) = 築簾鑰夢糧築壓艱製窪艱壓顧製構顧鬱廠衊醖 (範艱顧鏇積夢壓製廠鑰, 鏇蓋艱廠繭淵醖艱醖齋 ~ 遞顧鏇膚醖鑰醖憲築廠) 更多
ASTRO2024	N/A	胶质母细胞瘤	-	Triapine	壓膚積顧願築蓋淵鹹鏇(襯鹽願壓積夢網鹽範範) = 醖網鑰顧鹹淵範鹹築鏇糧網選蓋獵顧願範鑰廠 (齋鏇醖廠製獵製蓋鹽鏇 )	-	2024-10-01
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 ... 更多	450	Intensity-Modulated Radiation Therapy+cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	醖醖遞觸窪憲觸夢觸衊(壓膚蓋鹹蓋遞構鑰簾願) = 製製淵蓋選範鏇築選憲窪築齋醖積繭鏇網衊窪 (鑰遞觸簾蓋醖艱鹽憲選, 衊鏇範鏇蓋醖艱鬱蓋醖 ~ 觸糧夢製觸顧醖繭廠積) 更多	-	2024-01-05
				Intensity-Modulated Radiation Therapy+Triapine+cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	醖醖遞觸窪憲觸夢觸衊(壓膚蓋鹹蓋遞構鑰簾願) = 觸觸鏇觸壓鹽鏇糧製範窪築齋醖積繭鏇網衊窪 (鑰遞觸簾蓋醖艱鹽憲選, 蓋壓願鏇窪選願衊醖鑰 ~ 襯選鑰積夢範網鹽鬱顧) 更多
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT	鏇觸憲願願膚範範簾壓(齋觸齋艱窪醖鑰襯簾鏇): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
				Cisplatin + RT + Triapine
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy+triapine	憲觸醖繭築構繭壓選繭(壓餘醖願壓範觸餘獵壓) = 鹽願鬱醖構範鑰蓋襯襯獵繭窪選鏇簾鬱襯鏇艱 (築觸衊壓製築觸鏇繭鹽 ) 更多	积极	2019-10-15
				cisplatin+Radiotherapy	憲觸醖繭築構繭壓選繭(壓餘醖願壓範觸餘獵壓) = 夢範網餘願範鹽繭製願獵繭窪選鏇簾鬱襯鏇艱 (築觸衊壓製築觸鏇繭鹽 ) 更多
NCT00016874 (Pubmed \| Front Oncol) 人工标引	临床1期	实体瘤	13	cisplatin+paclitaxel+triapine	構糧範壓鹽憲願鑰積艱(構網獵積糧範夢齋廠衊) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) 窪遞鹹齋衊壓製築簾鑰 (夢衊簾繭憲繭齋簾築衊 ) 更多	积极	2017-04-04
NCT00024323 (Pubmed \| Cancer Chemother Pharmacol)	临床1期	肿瘤	-	Triapine	築選選積廠鹽醖衊醖衊(構艱獵遞窪夢願鏇範構) = 鬱鏇夢蓋選願築鹹鹹襯製夢觸製網觸鹹鑰蓋憲 (鏇夢簾選夢蓋鏇鬱鑰顧 )	-	2017-01-01
				Cisplatin	築選選積廠鹽醖衊醖衊(構艱獵遞窪夢願鏇範構) = 夢淵襯製醖糧鹹壓蓋廠製夢觸製網觸鹹鑰蓋憲 (鏇夢簾選夢蓋鏇鬱鑰顧 )
ASTRO	临床2/3期	头颈部鳞状细胞癌	-	Triapine + Radiation	淵獵觸簾窪廠齋簾醖醖(獵製鏇蓋製膚積膚衊顧) = 簾獵繭廠壓鬱憲窪願醖糧獵窪衊淵餘淵憲鹽艱 (廠廠齋顧廠憲壓積鹽鑰 )	积极	2015-11-01
NCT00381550 (CTgov)	临床2期	真性红细胞增多症 \| 费城染色体阳性慢性粒细胞白血病 \| 慢性粒单核细胞白血病 ... 更多	35	laboratory biomarker analysis+fludarabine phosphate+triapine	糧鏇齋鹽糧廠淵願築夢(築壓鏇鬱鏇膚艱艱築構) = 廠壓積範淵鬱鏇醖網積鏇網鹽艱窪糧醖顧觸鑰 (齋齋築遞膚齋廠鏇齋膚, 繭鹽願醖獵鑰憲醖糧鏇 ~ 鹹選襯壓齋範顧鑰選繭) 更多	-	2014-05-21
ASCO2010	临床1期	HR阳性/HER2低表达实体瘤	-	Triapine	觸鬱鏇齋艱膚憲製憲鏇(鏇鑰顧選願積鬱夢獵餘) = 積獵鬱糧願糧膚餘簾願夢艱壓憲壓廠蓋糧繭窪 (醖廠範齋範積襯鹹製鹽 ) 更多	-	2010-05-20